-
1.发明申请公开(公告)号：US20120135888A1
公开(公告)日：2012-05-31
申请号：US13138848
申请日：2010-04-12
申请人： Pieter Jacob Boender , Richard De Wijn , Anne Hansen Ree , Sigurd Folkvord , Kjersti Flatmark , Robby Ruijtenbeek
发明人： Pieter Jacob Boender , Richard De Wijn , Anne Hansen Ree , Sigurd Folkvord , Kjersti Flatmark , Robby Ruijtenbeek
CPC分类号： C12Q1/485 , G01N33/57419
摘要： The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.
摘要翻译： 本发明涉及一种用于确定或预测诊断为局部晚期直肠癌的患者对放化疗的反应的方法。 本发明还旨在提供用于预测诊断为直肠癌的患者对特定药物，放射治疗和/或化学疗法的反应的方法和装置。 更具体地，本发明提供了通过研究所述患者的样品中的磷酸化水平和分布来测量激酶活性的方法。
-
2.发明授权公开(公告)号：US08617836B2
公开(公告)日：2013-12-31
申请号：US13138848
申请日：2010-04-12
申请人： Pieter Jacob Boender , Richard De Wijn , Anne Hansen Ree , Sigurd Folkvord , Kjersti Flatmark , Robby Ruijtenbeek
发明人： Pieter Jacob Boender , Richard De Wijn , Anne Hansen Ree , Sigurd Folkvord , Kjersti Flatmark , Robby Ruijtenbeek
IPC分类号： C12Q1/48
CPC分类号： C12Q1/485 , G01N33/57419
摘要： The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.
摘要翻译： 本发明涉及一种用于确定或预测诊断为局部晚期直肠癌的患者对放化疗的反应的方法。 本发明还旨在提供用于预测诊断为直肠癌的患者对特定药物，放射治疗和/或化学疗法的反应的方法和装置。 更具体地，本发明提供了通过研究所述患者的样品中的磷酸化水平和分布来测量激酶活性的方法。
-
公开(公告)号：US20110257025A1
公开(公告)日：2011-10-20
申请号：US12736467
申请日：2009-04-10
申请人： René Houtman , Robby Ruijtenbeek , Pieter Jacob Boender , Marinus Gerardus Johannes Van Beuningen , Maria Helena Hilhorst , Richard De Wijn
发明人： René Houtman , Robby Ruijtenbeek , Pieter Jacob Boender , Marinus Gerardus Johannes Van Beuningen , Maria Helena Hilhorst , Richard De Wijn
CPC分类号： G01N33/574 , C12Q1/485
摘要： The present invention relates to methods for identifying classification markers for tumors by monitoring the activity of protein kinases. By acquiring a phosphorylation profile of diseased and control tissue samples the method of the present invention provides classification procedures using phosphorylation patterns enabling the distinction between different types and/or sub-types of tumors. Specific classification markers for tumors can be identified enabling tumor classification, diagnosis, prognosis and/or prediction of the clinical outcome of a therapy.
摘要翻译： 本发明涉及通过监测蛋白激酶的活性来鉴定肿瘤分类标记物的方法。 通过获得患病和对照组织样品的磷酸化特征，本发明的方法提供使用能够区分不同类型和/或亚型肿瘤的磷酸化模式的分类程序。 可以鉴定肿瘤的特异性分类标记物，其能够进行治疗的临床结果的肿瘤分类，诊断，预后和/或预测。
-
4.发明申请TREATMENT AND DIAGNOSIS OF METASTATIC PROSTATE CANCER WITH INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 审中-公开治疗和诊断与EPIDERM生长因子受体（EGFR）的抑制剂分离前列腺癌公开(公告)号：US20100203043A1
公开(公告)日：2010-08-12
申请号：US12450743
申请日：2008-04-11
IPC分类号： A61K39/395 , A61K31/5377 , A61K31/517 , A61K31/4706 , A61K38/09 , A61P35/00 , A61P35/04 , G01N33/53
CPC分类号： A61K31/517 , A61K31/167 , A61K31/4706 , G01N33/57434 , G01N2800/50 , G01N2800/52 , A61K2300/00
摘要： The present invention relates to a method for the treatment, prevention and/or diagnosis of metastatic prostate cancer. More specifically inhibitors of Epidermal Growth Factor Receptor (EGFR) are used in the preparation of a pharmaceutical composition for treating or preventing metastatic prostate cancer. The EGFR inhibitors can for instance be EGFR inhibitors, EGFR signaling inhibitors and/or inhibitors of kinases downstream of EGFR kinases. The EGFR inhibitors can also be used in detection, screening, prediction and treatment monitoring methods for metastatic prostate cancer.
摘要翻译： 本发明涉及一种治疗，预防和/或诊断转移性前列腺癌的方法。 更具体地，表皮生长因子受体（EGFR）的抑制剂用于制备用于治疗或预防转移性前列腺癌的药物组合物。 EGFR抑制剂可以例如是EGFR抑制剂，EGFR信号传导抑制剂和/或EGFR激酶下游的激酶抑制剂。 EGFR抑制剂也可用于转移性前列腺癌的检测，筛选，预测和治疗监测方法。
-
5.发明申请METHOD FOR PREDICTING TYROSINE KINASE INHIBITOR (TKI) RESISTANCE IN PATIENTS SUFFERING FROM CHRONIC MYELOGENOUS LEUKEMIA (CML) 审中-公开用于预测慢性髓性白血病（CML）患者的酪氨酸激酶抑制剂（TKI）耐药性的方法公开(公告)号：US20130217055A1
公开(公告)日：2013-08-22
申请号：US13879046
申请日：2011-10-17
申请人： Pieter Jacob Boender , Adriana Van Den Berg , Robby Ruijtenbeek , Jeroen Johannes Wilhelmus Maria Janssen , Gerrit Johan Ossenkoppele
发明人： Pieter Jacob Boender , Adriana Van Den Berg , Robby Ruijtenbeek , Jeroen Johannes Wilhelmus Maria Janssen , Gerrit Johan Ossenkoppele
IPC分类号： C12Q1/48
CPC分类号： C12Q1/485 , G01N33/57426 , G01N2333/9121
摘要： The present invention relates to a method for determining or predicting the response of a patient diagnosed with chronic myelogenous leukaemia (CML) to treatment with a tyrosine kinase inhibitor. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof thereby diagnosing CML patients resistant to treatment with Imatinib.
摘要翻译： 本发明涉及用于确定或预测诊断为慢性骨髓性白血病（CML）的患者对用酪氨酸激酶抑制剂治疗的反应的方法。 更具体地，本发明提供了通过研究磷酸化水平及其特征及其抑制来测定激酶活性的方法，由此诊断耐药用伊马替尼治疗的CML患者。
-
6.发明授权Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy 有权预测非小细胞肺癌患者对靶向药物治疗反应的方法公开(公告)号：US08962267B1
公开(公告)日：2015-02-24
申请号：US13138843
申请日：2010-04-12
申请人： Richard De Wijn , Robby Ruijtenbeek , Maria Helena Hilhorst , Michael Maria Van Den Heuvel , Houke Marian Klomp
发明人： Richard De Wijn , Robby Ruijtenbeek , Maria Helena Hilhorst , Michael Maria Van Den Heuvel , Houke Marian Klomp
CPC分类号： G01N33/57423 , C12Q1/485 , G01N2333/91205 , G01N2800/52
摘要： The present invention relates to a method for determining or predicting the response of a patient diagnosed with non small cell lung cancer to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non small cell lung cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.
摘要翻译： 本发明涉及一种用于确定或预测诊断为非小细胞肺癌的患者对靶向药物治疗的反应的方法。 本发明还旨在提供用于预测诊断为非小细胞肺癌的患者对具体药物的反应的方法和装置。 更具体地，本发明提供了通过研究所述患者样品中的药物的磷酸化水平及其特征和抑制来测量激酶活性的方法。
-
7.发明申请METHOD FOR DETERMINING SURIVIVAL PROGNOSIS OF PATIENTS SUFFERING FROM NON-SMALL CELL LUNG CANCER (NSCLC) 有权确定非小细胞肺癌（NSCLC）患者生存预后的方法公开(公告)号：US20130017963A1
公开(公告)日：2013-01-17
申请号：US13138849
申请日：2010-04-12
IPC分类号： C40B30/04
CPC分类号： G01N33/57423 , C12Q1/485
摘要： The present invention relates to a method for determining the survival prognosis of patients suffering from non-small cell lung cancer. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels in response to a kinase inhibitor and profiles in samples obtained from patients diagnosed with non-small cell lung cancer. The present invention also provides methods for predicting the response of a patient diagnosed with non-small cell lung cancer to a medicament.
摘要翻译： 本发明涉及一种确定患有非小细胞肺癌患者的生存预后的方法。 更具体地，本发明提供了通过研究响应于激酶抑制剂的磷酸化水平和从诊断为非小细胞肺癌的患者获得的样品中的分布来测量激酶活性的方法。 本发明还提供了用于预测诊断为非小细胞肺癌的患者对药物的反应的方法。
-
8.发明授权Method for determining survival prognosis of patients suffering from non-small cell lung cancer (NSCLC) 有权确定患有非小细胞肺癌（NSCLC）患者生存预后的方法公开(公告)号：US08962268B2
公开(公告)日：2015-02-24
申请号：US13138849
申请日：2010-04-12
CPC分类号： G01N33/57423 , C12Q1/485
摘要： The present invention relates to a method for determining the survival prognosis of patients suffering from non-small cell lung cancer. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels in response to a kinase inhibitor and profiles in samples obtained from patients diagnosed with non-small cell lung cancer. The present invention also provides methods for predicting the response of a patient diagnosed with non-small cell lung cancer to a medicament.
摘要翻译： 本发明涉及一种确定患有非小细胞肺癌患者的生存预后的方法。 更具体地，本发明提供了通过研究响应于激酶抑制剂的磷酸化水平和从诊断为非小细胞肺癌的患者获得的样品中的分布来测量激酶活性的方法。 本发明还提供了用于预测诊断为非小细胞肺癌的患者对药物的反应的方法。
-
公开(公告)号：US20120115754A1
公开(公告)日：2012-05-10
申请号：US13138850
申请日：2010-04-12
CPC分类号： G01N33/57438 , G01N33/57496 , G01N2800/52 , G01N2800/60
摘要： The present invention relates to a method for diagnosing, typing and/or subtyping renal cell carcinoma as well as predicting the response to medication of patients suffering from renal cell carcinoma. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.
摘要翻译： 本发明涉及一种用于诊断，分型和/或分型肾细胞癌的方法，以及预测患有肾细胞癌的患者对药物的反应。 更具体地，本发明提供了通过研究所述患者的样品中的磷酸化水平和分布来测量激酶活性的方法。
-
公开(公告)号：US09075061B2
公开(公告)日：2015-07-07
申请号：US13138847
申请日：2010-04-12
申请人： Robby Ruijtenbeek , Maria Helena Hilhorst , Arzu Umar , Johannes Albert Foekens , Johannes Wilhelmus Maria Martens
发明人： Robby Ruijtenbeek , Maria Helena Hilhorst , Arzu Umar , Johannes Albert Foekens , Johannes Wilhelmus Maria Martens
IPC分类号： C12Q1/48 , C40B40/10 , C40B30/08 , G01N33/574 , G01N33/74
CPC分类号： G01N33/57415 , C12Q1/485 , G01N33/74 , G01N2333/723 , G01N2800/52
摘要： The present invention relates to a method for determining the estrogen receptor status of patients suffering from breast cancer. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with breast cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples obtained from patients diagnosed with breast cancer.
摘要翻译： 本发明涉及确定患有乳腺癌的患者的雌激素受体状态的方法。 本发明还旨在提供用于预测诊断为乳腺癌的患者对具体药物的反应的方法和装置。 更具体地，本发明提供了通过研究从诊断为乳腺癌的患者获得的样品中的磷酸化水平和特征来测量激酶活性的方法。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.023 秒)
